Heterocyclic amides as kinase inhibitors
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsNiall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds having the formula (I): wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
Claims31
A compound according to Formula (I):
- wherein:
- R1 is (C1-C4)alkoxy-CH2—, phenyl(C1-C4)alkoxy-CH2—, or a substituted or unsubstituted (C2-C4)alkynyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(C1-C4)alkyl-group, or a substituted or unsubstituted 5-6 membered heterocycloalkyl group further optionally substituted by halogen or (C1-C4)alkyl,
- wherein said substituted (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-alkyl-, or 5-6 membered heterocycloalkyl group is substituted by 1, 2 or 3 substituents independently selected from hydroxyl, (benzyloxy)carbonyl)amino, cyano, halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkyl-CO—, cyano(C1-C4)alkyl-CO—, (C1-C4)alkoxy-(C1-C4)alkyl-CO—, (C1-C4)alkoxy-CO—, (C1-C4)alkylNHCO—, ((C1-C4)alkyl)((C1-C4)alkyl)NCO—, halo(C1-C4)alkyl-CO—, optionally substituted (C3-C6)cycloalkyl-CO—, optionally substituted (C3-C6)cycloalkyl-(C1-C4)alkyl-CO—, optionally substituted phenyl-CO—, optionally substituted phenyl-SO2—, optionally substituted phenyl(C1-C4)alkyl-CO—, optionally substituted 5-6 membered heteroaryl-CO—, and optionally substituted 9-10 membered heteroaryl-CO—,
- wherein said optionally substituted (C3-C6)cycloalkyl-CO—, optionally substituted (C3-C6)cycloalkyl-(C1-C4)alkyl-CO—, optionally substituted phenyl-CO—, optionally substituted phenyl-SO2-, optionally substituted phenyl(C1-C4)alkyl-CO—, optionally substituted 5-6 membered heteroaryl-CO—, or optionally substituted 9-10 membered heteroaryl-CO— is optionally substituted by 1 or 2 substituents independently selected from halogen, cyano, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkyl-CO—, halo(C1-C4)alkyl, halo(C1-C4)alkyl-CO—, (C3-C6)cycloalkyl and 5-6 membered heterocycloalkyl;
- or
- said substituted (C2-C4)alkynyl, (C3-C6)cycloalkyl or 5-6 membered heterocycloalkyl group is substituted by an optionally substituted phenyl, 5-6 membered heteroaryl or 9-membered heteroaryl group,
- wherein said phenyl, 5-6 membered heteroaryl or 9-membered heteroaryl group is optionally substituted by 1 or 2 substituents independently selected from halogen, (C1-C4)alkyl, (C1-C4)alkyl-CO—, halo(C1-C4)alkyl, and halo(C1-C4)alkyl-CO—;
- R2 is a substituted or unsubstituted phenyl, (C3-C6)cycloalkyl, 5-6 membered oxygen-containing heterocycloalkyl, 5-6 membered heteroaryl, 9-membered heteroaryl, 9-10 membered carbocyclic-aryl, or 9-10 membered heterocyclic-aryl group,
- wherein said substituted phenyl, (C3-C6)cycloalkyl, 5-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 9-membered heteroaryl, 9-10 membered carbocyclic-aryl, or 9-10 membered heterocyclic-aryl group is substituted by 1, 2 or 3 substituents independently selected from halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, and cyano;
- R3 is H or halogen;
- or a salt thereof,
- provided the compound is not:
- cyclohexyl(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone.
A compound of Formula (II) which is (S)-1-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperidin-1-yl)ethanone
- or a pharmaceutically acceptable salt thereof.
A compound of Formula (II) which is (S)-1-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperidin-1-yl)ethanone
Dependencies are inferred from the claim text.